RNTX
Rein Therapeutics Inc
NASDAQ: RNTX · HEALTHCARE · BIOTECHNOLOGY
$1.36
+6.27% today
Updated 2026-04-30
Market cap
$40.66M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.96
Dividend yield
—
52W range
$1 – $2
Volume
0.1M
Rein Therapeutics Inc (RNTX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | $63000.00 | $1000.00 |
| Gross profit | — | — | — | — | $-63000.00 | $-1000.00 |
| Gross margin | — | — | — | — | — | — |
| R&D | $11166.00 | $17008.00 | $17967.00 | $3991.00 | $14.25M | $11.03M |
| SG&A | $9330.00 | $9597.00 | $9680.00 | $11357.00 | $13.86M | $10.90M |
| Operating income | $-20496.00 | $-26605.00 | $-27647.00 | $-16276.00 | $-65.11M | $-21.93M |
| Operating margin | — | — | — | — | — | — |
| EBITDA | $-20333.00 | $-26484.00 | $-27478.00 | $-15229.00 | $-28.05M | $-21.93M |
| EBITDA margin | — | — | — | — | — | — |
| EBIT | $-20496.00 | $-26605.00 | $-27647.00 | $-15348.00 | $-28.11M | $-21.93M |
| Interest expense | — | — | — | — | — | — |
| Income tax | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-21157.00 | $-26164.00 | $-27329.00 | $-15732.00 | $-62.88M | $-49.87M |
| Net income growth (YoY) | — | -23.7% | -4.5% | +42.4% | -399614.0% | +20.7% |
| Profit margin | — | — | — | — | — | — |